期刊文献+

缬沙坦在临床中的应用 被引量:22

下载PDF
导出
摘要 目的:介绍缬沙坦的临床应用进展。方法:检索近年来国内外有关缬沙坦药理作用、药动学、临床应用及不良反应的文献。结果:缬沙坦作为一种血管紧张素II(AngII)受体拮抗剂,可拮抗AngII的AT1受体亚型,能降低血压,减轻心脏负荷,逆转心肌和血管壁平滑肌肥厚,降低肾小球内压,减少蛋白尿,延缓肝、肾间质纤维化的进程。结论:缬沙坦除用于治疗高血压外,还可用于治疗心力衰竭,急性心肌梗死,防止肝、肾纤维化,保护血管,减少糖尿病及其并发症的发生,治疗肾移植术后红细胞增多症和降低男性高血压患者性功能障碍的发生。
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2006年第8期1012-1014,共3页 Chinese Journal of Hospital Pharmacy
  • 相关文献

参考文献15

二级参考文献63

  • 1[1]Qunibi W Y,Barri Y, Devol E, et al. Factorspredictive of post-transplant erythrocytosis. KidneyInt, 1991,40:1153-1159.
  • 2[2]Fried W, Barone-Varelas J, Barone T,et al. Effect ofangiotensin infusion on extrarenal erythropoietinproduction. J Lab Clin Med, 1982,99:520-525.
  • 3[3]Julian B A, Brantley R R, Barker C V, et al.Losartan, an Angiotensin Ⅱ type 1 receptorantagonist, lowers hematocrit in posttransplanterythrocytosis. J Am Soc Nephrol, 1998, 9: 11041108.
  • 4[4]Mrug M, Stopka T, Julian B A,et al. Angiotensin Ⅱstimulate proliferation of normal early erythroidprogenitors. J Clin Invest, 1997,100: 2310-2314.
  • 5[5]Danovythch G M, Jamgotchian N J, Eggena P H,et al.Angiotension-converting enzyme inhibition in thetreatment of renal erythrocytosis.Transplantation,1995,60:132-137.
  • 6[1]THRMANN PA. Angiotensin II antagonism and the heart: valsartan in left ven tricular hypertrophy [J]. J Cardiovasc Pharmacol ,1999, 33 Suppl 1:S33-S36.
  • 7[2]PLUM J, BNTEN B, N**METH R, et al. Effects of the angiotensin II ant agonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients wit h chronic renal failure and hypertension [J]. J Am Soc Nephrol, 1998, 9(12): 2 223-2234.
  • 8[3]BREMNER AD, BAUR M, ODDOU-STOCK P, et al. Valsartan: long term effica cy and tolerability compared to lisinopril in elderly patients with essential hypertens ion [J]. Clin Exp Hypertens, 1997, 19(8): 1263-1285.
  • 9[4]MARKHAM A, GOA KL. Valsartan a review of its pharmacology and therapeutic use in essential hypertension [J]. Drugs ,1997 ,54(2): 299-311.
  • 10[5]BLACK HR, GRAFF A, SHUTE D, et al. Valsartan, a new angiotensin II ant agonis t for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril [J]. J Hu m Hypertens, 1997,11(8): 483-489.

共引文献133

同被引文献159

引证文献22

二级引证文献110

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部